"Updated efficacy and safety results from the phase 2 study of serplulimab, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors"

作者全名："Jin Li; Qin, Shukui; Zhong, Haijun; Chuan Jin; Chen, Lili; Yuan, Xianglin; Fan, Qingxia; Chen, Kehe; Cao, Peiguo; Xiao, Jianjun; Da Jiang; Tao Zhang; Zhang, Hongyu; Wang, Xicheng; Wei Wang; Lin Han; Wang, Qingyu; Jun Zhu"

作者地址："Shanghai East Hosp, Shanghai, Peoples R China; Eastern Theater Gen Hosp PLA China, Qinhuai Med Area, Nanjing, Peoples R China; Zhejiang Canc Hosp, Hangzhou, Peoples R China; Affiliated Canc Hosp, Guangzhou, Peoples R China; Inst Guangzhou Med Univ, Guangzhou, Peoples R China; Taizhou First Peoples Hosp, Taizhou, Peoples R China; Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China; Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China; Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China; Cent South Univ, Xiangya Hosp 3, Changsha, Peoples R China; Zhongshan City Peoples Hosp, Zhongshan, Peoples R China; Hebei Med Univ, Dept Med Oncol, Hosp 4, Shijiazhuang, Peoples R China; Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China; Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China; Guangdong Pharmaceut Univ, Affiliated Hosp 1, Sch Clin Med, Guangzhou, Peoples R China; First Peoples Hosp Foshan, Foshan, Peoples R China; Shanghai Henlius Biotech Inc, Shanghai, Peoples R China"

通信作者：　

来源：JOURNAL OF CLINICAL ONCOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000863680300815

JCR分区：Q1

影响因子：45.3

年份：2022

卷号：40

期号：16

开始页：　

结束页：　

文献类型：Meeting Abstract

关键词：　

摘要：　

基金机构："Shanghai Henlius Biotech, Inc."

基金资助正文："Shanghai Henlius Biotech, Inc."